68Ga-labeled prostate-specific membrane antigen is a novel PET/CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study
The Journal of Nuclear Medicine Feb 06, 2019
Kesler M, et al. - In this prospective pilot study, researchers evaluated the possible role of 68Ga-prostate-specific membrane antigen (PSMA) PET/CT in hepatocellular carcinoma (HCC) imaging. Study participants included 7 patients who had HCC with 41 liver lesions (37 suspected malignant lesions[tumor lesions] and 4 regenerative nodules). According to findings, 36 of the 37 tumor lesions and none of the regenerative nodules exhibited increased 68Ga-PSMA uptake, and only 10 lesions were 18F-FDG–avid. For imaging HCC patients, 68Ga- PSMA PET/CT was better than 18F-FDG PET/CT. Findings suggested that it is more common for HCC lesions to be hypervascular, taking up 68Ga-PSMA in tumoral microvessels. For imaging patients with HCC, 68Ga-PSMA PET/CT is a possible novel modality.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries